Cargando…
Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza A and B virus infections in February 2018 in Japan. Because of the need to monitor influenza viruses for reduced susceptibility to this drug, we used two cell-based screening systems – a con...
Autores principales: | Takashita, Emi, Morita, Hiroko, Ogawa, Rie, Nakamura, Kazuya, Fujisaki, Seiichiro, Shirakura, Masayuki, Kuwahara, Tomoko, Kishida, Noriko, Watanabe, Shinji, Odagiri, Takato |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291754/ https://www.ncbi.nlm.nih.gov/pubmed/30574137 http://dx.doi.org/10.3389/fmicb.2018.03026 |
Ejemplares similares
-
Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018
por: Takashita, Emi, et al.
Publicado: (2019) -
Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil
por: Nakauchi, Mina, et al.
Publicado: (2020) -
Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019
por: Takashita, Emi, et al.
Publicado: (2019) -
Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019
por: Takashita, Emi, et al.
Publicado: (2019) -
The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor
por: Todd, Brendan, et al.
Publicado: (2021)